Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000221197

Medchemexpress LLC 1,2-benzisoselenazol-3(2H)-one, 2-[3-(trifluoromethyl)phenyl]- | 2570461-66-2 | 99.4% | 342.17 g·mol⁻¹ | C14H8F3NOSe | 5 MG
SDP

Catalog No. 5000221197
Encompass_Preferred

SARS-CoV-2-IN-7 is a small-molecule inhibitor that reduces SARS-CoV-2 replication in vitro, with a reported IC50 of 844 nM in infected Vero E6 cells. It is supplied for research use and is available as a solid or as DMSO solution in multiple package sizes.

  • Demonstrated antiviral activity in cell culture (IC50 844 nM).
  • High reported chemical purity (99.4%).
  • Available as solid (mg quantities) and 10 mM DMSO solution formats.
  • Molecular weight 342.17 g·mol⁻¹ and formula C14H8F3NOSe.
  • Suitable for in vitro assays and mechanistic studies of viral replication.

Catalog No. 50-002-21197 Supplier Medchemexpress LLC Supplier No. HY1418415MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

SARS-CoV-2-IN-7 is a small-molecule inhibitor that reduces SARS-CoV-2 replication in vitro, with a reported IC50 of 844 nM in infected Vero E6 cells. It is supplied for research use and is available as a solid or as DMSO solution in multiple package sizes.

  • Demonstrated antiviral activity in cell culture (IC50 844 nM).
  • High reported chemical purity (99.4%).
  • Available as solid (mg quantities) and 10 mM DMSO solution formats.
  • Molecular weight 342.17 g·mol⁻¹ and formula C14H8F3NOSe.
  • Suitable for in vitro assays and mechanistic studies of viral replication.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.